Actionable news
All posts from Actionable news

Neuroderm's (NDRM) CEO Oded Lieberman on Q3 2015 Results - Earnings Call Transcript

Roy Golan - Chief Financial Officer

Good morning and thanks for joining us today. With me is Oded Lieberman, CEO; Sheila Oren, VP of Clinical and Regulatory Affairs.

Before we begin, I would like to read the following regarding forward-looking statements. Certain statements in today's conference call and responses to various questions may constitute forward-looking statements. We wish to caution you that such statements reflect only the company's current expectations and that the actual events or results may differ materially.

For more information about factors that could impact these forward-looking statements, please refer to the risk factors contained in the company's most recent Form 20-F and subsequent filings with the Securities and Exchange Commission.

I will now turn the call over to Oded Lieberman.

Oded Lieberman - Chief Executive Officer

Thank you, Roy, and thank you everybody for joining us. On our call today, I’ll review our streamline clinical development program following feedback from the FDA. Roy will then review our third quarter financial results. After that, we will take your questions.

Earlier today, NeuroDerm announced a streamlined...